BWH and Broad Institute Fellowship Opportunity: Sperling Family Fellowship in Precision Healthcare

BWH and Broad Institute Fellowship Opportunity: Sperling Family Fellowship in Precision Healthcare

The Broad Institute of MIT and Harvard and Brigham and Women’s Hospital are pleased to announce a new fellowship opportunity. The Sperling Family Fellowship in Precision Healthcare will leverage the strengths of two world-renowned institutions— the superb clinical care, expert bioinformatics, and rich data sources of Brigham and Women’s Hospital, and the basic science, computational, and genomics sophistication of the Broad Institute – to advance a translational research project with the potential to transform how we care for patients.

Fellows will work under the auspices of both BWH and the Broad Institute on a translational research project that will help answer urgent clinical questions, eventually bringing findings to bear on care for individual patients and populations and advancing the field of precision medicine.

It is anticipated that the fellows will pursue the fundamental scientific aspects of his/her project at the Broad Institute while utilizing resources at BWH for clinical facets of the work. The fellow will have a mentor at both sites.

Senior postdoctoral fellows or faculty in their first two years of appointment are eligible to apply for one year of funding (with the ability to apply for a second year).  Applicants are expected to develop a proposal that addresses a clinically relevant problem that is best addressed with the data, methods and technologies at the Broad Institute. The successful recipient will be afforded appropriate space and support at the Broad Institute and BWH during the fellowship.

A complete application includes:

  • Cover letter
  • NIH Biosketch/CV
  • Research Statement (5 pages) and Budget
  • Letters of Support (no more than 3)



  • Call for proposals – Feb. 17, 2017
  • Application Deadline – March 31, 2017
  • Notification of Awards – April 28, 2017


Applications can be submitted to Claudia Rizzini, managing director, Precision Medicine, Department of Pathology, Brigham and Women’s Hospital.